Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.11 EUR | 0.00% | +4.71% | -17.80% |
Apr. 26 | Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 03 | Valbiotis: launch of Valbiotis PRO Cholesterol in May | CF |
Sales 2023 | 6.81M 7.3M | Sales 2024 * | 11M 11.79M | Capitalization | 64.83M 69.47M |
---|---|---|---|---|---|
Net income 2023 | -7M -7.5M | Net income 2024 * | -6M -6.43M | EV / Sales 2023 | 9.11 x |
Net cash position 2023 * | 19.83M 21.26M | Net cash position 2024 * | 11.8M 12.65M | EV / Sales 2024 * | 4.82 x |
P/E ratio 2023 * |
-4.4
x | P/E ratio 2024 * |
-4.67
x | Employees | 48 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 91.48% |
1 day | +4.31% | ||
1 week | +6.06% | ||
Current month | +13.22% | ||
1 month | +13.22% | ||
3 months | -2.84% | ||
6 months | -27.39% | ||
Current year | -17.80% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | - | |
Pascal Sirvent
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Sébastien Bessy
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Agnès Tixier
BRD | Director/Board Member | - | 19-03-17 |
Laurent Lévy
CHM | Chairman | 53 | 17-02-28 |
Chief Executive Officer | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 4.11 | 0.00% | 24 928 |
24-04-30 | 4.11 | +4.31% | 49,465 |
24-04-29 | 3.94 | +1.03% | 24,900 |
24-04-26 | 3.9 | -1.64% | 42,504 |
24-04-25 | 3.965 | +0.89% | 36,565 |
Real-time Euronext Paris, April 30, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.80% | 69.24M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+2.13% | 22.25B | |
-14.77% | 21.68B | |
-8.79% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- ALVAL Stock